Olaparib administered in high-grade serous and/or undifferentiated ovarian cancer patients showed a 41% and 24% objective response rate with or without BRCA1/2 mutations; however, there was no response in TNBC patients (Gelmon et al. 2011). This evidence concerns the gene BRCA1 and ovarian carcinoma.